Loan & DebtAug 5, 2026, 05:23 PM
AbbVie Issues $10B Senior Notes for Apogee Acquisition
AI Summary
AbbVie Inc. has entered into an underwriting agreement to issue and sell $10 billion aggregate principal amount of senior notes. The offering includes a mix of floating rate and fixed-rate notes with maturities ranging from 2028 to 2066. The net proceeds, estimated at approximately $9.93 billion, are intended to fund a portion of the cash payment for the acquisition of Apogee Therapeutics, Inc. and for other general corporate purposes, including potential debt repayment.
Key Highlights
- AbbVie issued $10 billion aggregate principal amount of senior notes.
- Proceeds will fund a portion of the cash payment for the Apogee Therapeutics, Inc. acquisition.
- Proceeds are also designated for general corporate purposes, including repayment or repurchase of outstanding debt.
- The offering included Floating Rate Notes due 2028 and various fixed-rate senior notes with maturities up to 2066.
- Expected net proceeds from the sale are approximately $9.93 billion.
- Morgan Stanley, BofA Securities, J.P. Morgan, and SG Americas Securities acted as underwriters.
- The closing of the sale of the Notes is expected to occur on August 18, 2026.
Price Impact
More from ABBV